Proposal for an ecofriendly and economic strategy for efficient radioiodination of coumarin derivatives

Combination of the calculation of reactivity descriptors and the cold iodine test for some coumarin derivatives was used in order to optimize the radioiodination reaction. The strongly nucleophilic predicted coumarins were subjected to the action of cold iodine. With two coumarins substituted at 3 by the 2-hydroxybenzoyl group, iodination did not occur but a product of intramolecular heterocyclization was obtained. This strategy is useful for economic and environmentally friendly radioiodination.publishe

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

A New Fracture Criterion under Multiaxial Monotonic Loading for Rubbers

International audienc

Fracture of elastomers under static mixed mode: the strain energy density factor

International audienceThis work deals with the fracture of rubbers under a mixed mode loading (I + II) and it is an extension of our previous papers on that subject [Aït Hocine N, Naït Abdelaziz M, Imad A (2002) Int J Fract 117:1–23; Aït Hocine N, Naït Abdelaziz M (2004) In: Sih GC, Kermanidis B, Pantelakis G (eds) 6th international conference for mesomechanics. Patras (Greece), May 31–June 4, pp 381–385]. An experimental and a numerical analysis were carried out using a Styrene Butadiene Rubber (SBR) filled with 20 and 30% of carbon black. Sheets with an initial central crack (CCT specimens) inclined with a given angle compared to the loading direction were used. The J-integral and its critical values J c (fracture surface energy) were determined by combining experimental data and finite element results. These critical values, determined at the onset of crack growth, were found to be quite constant for each elastomer tested, which suggests that J c represents a reasonable fracture criterion of such materials. Then, the strain–stress field and the strain-energy-density factor S, earlier introduced by Sih [Sih GC (1974) Int J Fract 10(3):305–321; Sih GC (1991) Mechanics of fracture initiation and propagation. Kluwer Academic Publishers, Dordrecht, 428 pp] were numerically calculated around the crack tip. According to the experimental observations, the plan of crack propagation is perpendicular to the direction of the maximum principal stretch. Moreover, as suggested by Sih in the framework of linear elastic fracture mechanics (LEFM), the minimum values S min of the factor S are reached at the points corresponding to the crack propagation direction. These results suggest that the concept of the maximum principal stretch and the one of the strain-energy-density factor can be used as indicators of the crack propagation direction

A fracture criterion of rubber like materials under plane stress conditions

International audienceIn this work, we attempt to derive a fracture criterion for filled and unfilled elastomer vulcanizates and thermoplastics from a set of experimental data. Firstly, fracture criteria reported in the literature have been applied to experimental data obtained from tests including various loading modes (simple tension, equal biaxial tension and biaxial tension) and performed on four materials: a natural rubber (NR), a styrene butadiene rubber (SBR), a polyurethane (PU) and a thermoplastic elastomer (TPE).Then, a new failure criterion based on an equivalent elongation concept is proposed. This equivalent elongation seems to be linearly dependent on a given biaxiality ratio, which leads to expressing the principal elongations at break as functions of both the biaxiality n and two experimental parameters. Quite good agreement is highlighted when comparing the failure experimental data with the proposed criterion for the tested elastomers

J integral as a fracture criterion of rubber-like materials using the intrinsic defect concept

International audienc

Experimental and finite element investigation of void nucleation in rubber-like materials

International audienc

Development of a Novel Adsorbent Prepared from Dredging Sediment for Effective Removal of Dye in Aqueous Solutions

This study proposed a novel and low-cost adsorbent prepared from dredging sediment (DSD) for effective removal of dye in aqueous solutions. The adsorption efficiency and behavior of the DSD adsorbent toward the crystal violet (CV), a cationic dye, were investigated via batch experiments. The results showed that DSD samples contain mainly clay minerals (illite and kaolinite) and other mineral phases. In addition, DSD is a mesoporous material (Vmesopore = 94.4%), and it exhibits a relatively high surface area (~39.1 m2/g). Adsorption experiments showed that the solution’s pH slightly affects the adsorption process, and a pH of 11 gave a maximum capacity of 27.2 mg/g. The kinetic data of CV dye adsorption is well described by the pseudo–second-order and the Avrami models. The Langmuir and Liu isotherm models provide the best fit for the adsorption equilibrium data. The monolayer adsorption capacity of Langmuir reached 183.6, 198.0, and 243.6 mg/g at 293, 308, and 323 K, respectively. It was also found that the adsorption process was spontaneous (−ΔG°), exothermic (−∆H°), and increased the randomness (+∆S°) during the adsorption operation. The primary mechanisms in CV dye adsorption were ion exchange and pore filling, whereas electrostatic attraction was a minor contribution. In addition, three steps involving intraparticle diffusion occur at the same time to control the adsorption process. The results of this study highlight the excellent efficiency of DSD material as an ecofriendly sorbent for toxic dyes from water media